Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05216835 · ClinicalTrials.gov registry record · Phase 1
Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
A Phase 1 study of Relapsed or Refractory Classical Hodgkin Lymphoma, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 14
- Study locations
NCT05216835 is a Phase 1 study of Relapsed or Refractory Classical Hodgkin Lymphoma that has completed, run by AstraZeneca. The registered enrollment target is 45 participants. The trial reports 14 study locations across 8 states.
The verdict
NCT05216835, a Phase 1 study of Relapsed or Refractory Classical Hodgkin Lymphoma, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 14
- Study locations
Study Summary
The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sabestomig (AZD7789) in patients with relapsed/refractory classical Hodgkin Lymphoma (r/r cHL).
Conditions Studied
Interventions
- DRUG Sabestomig (AZD7789)
Study Locations (14)
Other
- Research Site - København Ø
- Research Site - Lille
- Research Site - Bologna
- Research Site - Naples
- Research Site - Valencia
- Research Site - Manchester
- Research Site - Oxford
California
- Research Site - Duarte
Florida
- Research Site - Miami
Minnesota
- Research Site - Rochester
New York
- Research Site - New York
Texas
- Research Site - Houston
Ontario
- Research Site - Toronto
Quebec
- Research Site - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-03-18 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05216835
The ClinicalTrials.gov registry entry for NCT05216835 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory Classical Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Sabestomig (AZD7789) is the first listed.
NCT05216835 reports 14 study locations spanning 8 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT05216835 about?
NCT05216835 is a clinical study titled "Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma". The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sabestomig (AZD7789) in patients with relapsed/refractory classical Hodgkin Lymphoma (r/r cHL).
What is the current status of trial NCT05216835?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2022-03-18. Estimated completion is 2025-09-04.
What conditions does trial NCT05216835 study?
This clinical trial studies the following conditions: Relapsed or Refractory Classical Hodgkin Lymphoma.
What interventions are being tested in trial NCT05216835?
The interventions under investigation include: Sabestomig (AZD7789) (DRUG).
Who is sponsoring clinical trial NCT05216835?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05216835 being conducted?
This trial has 14 study locations across California, Florida, Minnesota, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.